Erfonrilimab - Alphamab
Alternative Names: Anti-PD-L1 / CTLA-4 bispecific antibody; KN-046Latest Information Update: 05 Apr 2024
At a glance
- Originator Alphamab
- Developer Beijing Cancer Hospital; InxMed; Jiangsu Alphamab Biopharmaceuticals; Peking University; Shanghai Pulmonary Hospital; Suzhou Kintor Pharmaceuticals; Weill Cornell Medical College
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer; Pancreatic cancer
- Phase II/III Malignant thymoma
- Phase II Digestive system neoplasms; Gastric cancer; Liver cancer; Oesophageal cancer; Solid tumours
- Phase I/II Triple negative breast cancer
- Phase I Lymphoma
Most Recent Events
- 15 Mar 2024 Peking University Cancer Hospital & Institute completes a phase II trial in Liver cancer (First-line therapy, Combination therapy, Late-stage disease, In adults, In the elderly) in China (IV) (NCT04542837)
- 12 Mar 2024 Jiangsu Alphamab Biopharmaceuticals terminates a phase II trial for Malignant thymoma (Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy) in China due to the adjustment of the sponsor's development strategy(NCT04469725)
- 12 Dec 2023 Safety and efficacy data from a phase I/II trial in Solid tumours and Lymphoma presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)